The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic EGFR-mutated non–small cell lung cancer (NSCLC).
 
Regan Memmott
Consulting or Advisory Role - J&J Innovative Medicine; Orion
Travel, Accommodations, Expenses - J&J Innovative Medicine; Orion
 
Jinesh Gheeya
Honoraria - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - IASLC
 
Lai Wei
No Relationships to Disclose
 
Nicole Abbott
No Relationships to Disclose
 
Kasey Hill
No Relationships to Disclose
 
Joo Na
No Relationships to Disclose
 
Mitch Phelps
Honoraria - Genentech/Roche
Consulting or Advisory Role - BridgeBio Pharma; DTx Pharma
Patents, Royalties, Other Intellectual Property - This is a licensing agreement for use patents for HOSU-53, an anti-cancer drug that is now in early phase (first-in-human) clinical evaluation.
Travel, Accommodations, Expenses - Genentech/Roche
 
Wancai Yang
No Relationships to Disclose
 
David Stenehjem
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Aprea Therapeutics; Biolojic; Dracen; In Silico; Indaptus; Iterion Therapeutics; Schrodinger
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); SpringWorks Therapeutics (Inst)
 
Stephen Horrigan
Employment - Iterion Therapeutics
Leadership - Iterion Therapeutics
Stock and Other Ownership Interests - Iterion Therapeutics
Consulting or Advisory Role - HBV tech Inc.; Neuimmune Inc.
Patents, Royalties, Other Intellectual Property - Iterion Therapeutics
Travel, Accommodations, Expenses - Iterion Therapeutics
 
Aundrietta Duncan
No Relationships to Disclose
 
Dudbeth Brown
No Relationships to Disclose
 
Jacob Kaufman
No Relationships to Disclose
 
Asrar Alahmadi
Consulting or Advisory Role - Amgen; Association of cancer care centers; AstraZeneca; Catalyst Pharmaceuticals; Daiichi Sankyo; Jazz Pharmaceuticals; Rigel
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; oncoc4; Perthera; Pfizer; Synthekine
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Mingjia Li
No Relationships to Disclose
 
Carolyn Presley
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Onc Live; Regeneron
 
Timothy Burns
Consulting or Advisory Role - Adcendo Aps; Advarra; AstraZeneca; Bristol Myers Squibb; Caris Life Sciences; Genentech; Janssen Scientific Affairs; Lilly; Pfizer
Research Funding - Novartis (Inst)
 
Dwight Owen
Honoraria - Chugai Pharma; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Nuvalent, Inc. (Inst); Onc.AI (Inst); Palobiofarma (Inst); Pfizer (Inst); Tango Therapeutics (Inst); Tubulis GmbH (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Genentech; Janssen Biotech
 
David Carbone
Employment - James Cancer Center
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; EMD Serono; Gilead Sciences; Iovance Biotherapeutics; Janssen; Johnson & Johnson/Janssen; Lilly; Lumanity; Merck; Merck KGaA; OncLive/MJH Life Sciences; Oncohost; Pfizer; Regeneron; Roche/Genentech; Synthekine
Research Funding - Genentech (Inst)